Our analysis of de novo sphingolipid synthesis of mutant SPTLC2 in patient derived fibroblasts were consistent with the biochemical mechanism previously reported in SPTLC1-associated ALS patients. The gene discussed is SPTLC1; the disease is amyotrophic lateral sclerosis.